TIL
$8.57+0.36 (+4.38%)
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in...
Recent News
CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround
CarMax runs a nationwide network of used car stores and digital channels, offering multi-channel sales and financing to U.S. consumers.
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition.
Instil Bio, Inc. (NASDAQ:TIL) is definitely on the radar of institutional investors who own 36% of the company
NasdaqCM:TIL 1 Year Share Price vs Fair Value Explore Instil Bio's Fair Values from the Community and select yours Key...
Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know
Does Instil Bio, Inc. (TIL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet
The mean of analysts' price targets for Instil Bio (TIL) points to a 246.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.